scout
|Videos|March 24, 2014

Dr. Petrylak on Custirsen in Prostate Cancer

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase III trial measuring the efficacy of custirsen plus docetaxel versus docetaxel alone in patients with prostate cancer (SYNERGY trial).

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase III trial measuring the efficacy of custirsen plus docetaxel versus docetaxel alone in patients with prostate cancer (SYNERGY trial).

Petrylak believes the science behind custirsen is good. Custirsen is a second-generation antisense inhibitor of clusterin​​, which may play a fundamental role in cancer cell survival and treatment resistance.

In a phase II trial, prostate cancer patients experienced a survival benefit when treated with custirsen. The results of the phase III trial should read out this year, Petrylak says.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME